The Centers for Disease Control and Prevention reported that US kindergarten vaccination rates declined for the 2025-26 school year, while exemption rates climbed to an all-time high. The data reflect persistent vaccine hesitancy and eroding herd immunity, raising the risk of measles and pertussis outbreaks. For vaccine manufacturers such as Merck, GSK, and Sanofi, the trend signals weaker demand for routine childhood immunizations, pressuring pediatric vaccine sales.
Merck manufactures MMR (M-M-R II) and varicella (Varivax) vaccines required for US kindergarten entry. A decline in kindergarten vaccination rates and record exemptions directly reduces demand for these products, pressuring Merck's pediatric vaccine revenue.
- ▼ US kindergarten vaccination rates fell again for 2025-26
- ▼ Exemptions hit record high, signaling declining routine immunization
- ▲ Outbreaks could spur catch-up vaccination demand
- ▲ Policy changes mandating vaccines could reverse trend
▼ Show FAQ (2) ▲ Hide FAQ
How does falling kindergarten vaccination rates impact Merck?
Merck's MMR and varicella vaccines are core pediatric products. Lower coverage reduces demand for these vaccines, cutting into Merck's vaccine sales.
Could Merck benefit from a disease outbreak?
An outbreak could trigger catch-up immunization campaigns, but the current trend of rising exemptions points to a sustained decline in routine vaccine uptake.